SOLANA BEACH, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Professor Saoirse O'Sullivan, Artelo's Vice President of Translational Sciences, will be presenting at the 13th Congress of the European Pain Federation (EFIC) being held September 20-22, 2023 at the HUNGEXPO Exhibition Centre in Budapest, Hungary.
Professor O'Sullivan's presentation, titled, "Effects of the FABP5 Inhibitor, ART26.12, in Oxaliplatin-Induced Peripheral Neuropathy in Rats," is scheduled for 6:30 a.m. ET / 12:30 p.m. CEST on Wednesday, September 20, 2023.
The Company recently announced that it has completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration regarding the manufacturing, preclinical and clinical development of ART26.12. Artelo plans to file an IND application for the use of ART26.12 in neuropathic pain in the first half of 2024.
To register for the event, please visit: 13th Congress of the European Pain Federation.
About ART26.12
Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids including endocannabinoids and fatty acids. Various inhibitors of FABPs may be particularly useful for the treatment of specific cancers, neuropathic and nociceptive pain, and anxiety disorders. ART26.12, Artelo's lead FABP inhibitor compound, is a selective inhibitor of FABP5. While ...